Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rare coagulation disorders.

F Peyvandi1, P M Mannucci

  • 1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, IRCCS Maggiore Hospital and University of Milano, Italy.

Thrombosis and Haemostasis
|November 2, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced circulating FABP2 in patients with moderate to severe COVID-19 may indicate enterocyte functional change rather than cell death.

Scientific reports·2022
Same author

Lombardy diagnostic and therapeutic network of thrombotic microangiopathy.

Orphanet journal of rare diseases·2022
Same author

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

ESMO open·2022
Same author

Evaluation of procoagulant imbalance in Cushing's syndrome after short- and long-term remission of disease.

Journal of endocrinological investigation·2021
Same author

Evolution of Haemophilia Care in Europe: 10 years of the principles of care.

Orphanet journal of rare diseases·2020
Same author

COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
Same journal

Methylglyoxal Promotes RBC-Driven Procoagulant Activity and Venous Thrombosis under Diabetes-Relevant Conditions.

Thrombosis and haemostasis·2026
Same journal

Management of Inferior Vena Cava Thrombosis: Guidance from the Italian Society for the Study of Haemostasis and Thrombosis.

Thrombosis and haemostasis·2026
See all related articles

Recessive coagulation disorders present varied bleeding symptoms, with Factor X and II deficiencies being most severe. Safe treatment options like inactivated plasma and factor concentrates are recommended for these rare inherited conditions.

Area of Science:

  • Hematology
  • Genetics
  • Internal Medicine

Background:

  • Recessive coagulation disorders are rare globally but more prevalent in Iran due to consanguineous marriages.
  • Optimal treatment and bleeding patterns for these disorders are less understood compared to hemophilia and von Willebrand disease.

Purpose of the Study:

  • To evaluate bleeding symptoms in Iranian patients with inherited deficiencies of fibrinogen, factor II, combined factor V and VIII, factor V, factor VII, and factor X.
  • To determine the severity of clinical manifestations and guide optimal treatment strategies.

Main Methods:

  • Retrospective analysis of 237 Iranian patients with inherited recessive coagulation disorders.
  • Classification of bleeding symptoms into severe (life-endangering) and mild categories.

Related Experiment Videos

  • Assessment of clinical manifestations including CNS, gastrointestinal, umbilical cord bleeding, hematomas, and hemarthroses.

    • Main Results:

    • Factor X and Factor II deficiencies were associated with the most severe bleeding manifestations.
    • Most patients with other recessive defects experienced milder bleeding, with few life-endangering hemorrhages or disabilities.
    • A minority of patients, even with undetectable plasma levels, had severe outcomes.

    Conclusions:

    • The clinical severity of recessive coagulation disorders varies, with Factor X and II deficiencies being the most severe.
    • Mild clinical manifestations are common in other recessive coagulation disorders, even with low factor levels.
    • Virally inactivated plasma and factor concentrates are recommended as safe and preferred treatment options due to the mild nature of most recessive coagulation disorders.